If a patient is unable to tolerate one CDK 4/6 inhibitor, do you switch to a different one?

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Metastatic • Breast Cancer, Non-metastatic

For example, a patient has had multiple dose reductions for neutropenia and required an admission for infection while on palbociclib. Would you switch to abemaciclib?

Answer from: Medical Oncologist at Community Practice

There are currently no data about switching from one CDK 4/6 inhibitor to another. The current recommendations for palbociclib with grade 3 neutropenia and infection are to hold palbociclib until recovery to grade 2 or less and then dose reduce. It sounds as though this patient has required multiple...

Answer from: Medical Oncologist at Academic Institution

I agree. I have had success switching from palbociclib to abemaciclib for patients with neutropenia, and from one CDK4/6 inhibitor to another for a patient with cutaneous toxicity.

Comments

Medical Oncologist at Cleveland Clinic Taussig Cancer Institute
How about if the patient develops pneumonitis from...

Answer from: Medical Oncologist at Community Practice

Yes

Related Questions